anti-ACE2 (human), mAb (blocking) (AC384) (preservative free)
Methods: Spike (SARS-CoV-2):Fc (human) (RBD) (rec.) (AG-40B-0194) is coated on an ELISA plate at 1µg/ml. ACE2 (human), mAb (blocking) (AC384) (AG-20A-0037PF) or an unrelated mAb Control are added (starting at 40µg/ml with a two-fold serial dilution) together with 500ng/µl of ACE2 (human) (AG-40B-0192). After incubation for 1h at RT, the binding was detected using an anti-FLAG antibody (HRP).
|Synonyms||SARS Receptor; Angiotensin-converting Enzyme 2; ACEH; Metalloprotease MPROT15; SARS-CoV-2 Receptor|
|Product Type||Monoclonal Antibody|
|Immunogen/Antigen||Recombinant human ACE2.|
ELISA: (direct or indirect: 1:2'000-1:10'000)
Functional Application: Blocks the binding of human ACE2 to the Spike protein of SARS-Cov-2. Does not affect the enzymatic activity of human ACE2.
Optimal conditions should be determined individually for each application.
Recognizes human ACE2.
|Purity Detail||Protein G-affinity purified.|
|Formulation||Liquid. In PBS.|
|Isotype Negative Control|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
|Use/Stability||Stable for at least 1 year after receipt when stored at -20°C.|
|Product Specification Sheet|
Angiotensin-converting enzyme2 (ACE2) is an ectoenzyme (carboxypeptidase) with an extracellular catalytic domain that predominantly localizes at the plasma membrane and is thereby able to hydrolyze circulating peptides. ACE2 has approximately 42% sequence identity with ACE and its cytoplasmic and transmembrane domains show 48% homology to the protein collectrin, that plays a critical role in the amino acid absorption of the kidney. ACE2 converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. ACE2 is involved in the regulation of systemic blood pressure and has direct effects on cardiac functions. It is expressed predominantly in endothelial cells of the lung, gut, heart and kidney. ACE2 together with the protease TMPRSS2 acts as a functional receptor for SARS coronavirus as well as for the new highly pathogenic coronavirus, 2019-nCoV/SARS-CoV-2, which is cause for pneumonia COVID-19.
- Development of an enzymatic assay for the detection of neutralizing antibodies against therapeutic angiotensin-converting enzyme 2 (ACE2): K. Liao, et al.; J. Immunol. Meth. 389, 52 (2013)
- Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications: VB. Patel, et al.; Clin. Sci. 126, 471 (2014)
- Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection In Vitro: F. Curreli, et al.; mBio 11, e02451 (2020)
- Pomegranate Peel Extract as an Inhibitor of SARS-CoV-2 Spike Binding to Human ACE2 Receptor (in vitro): A Promising Source of Novel Antiviral Drugs: A. Tito, et al.; Front. Chem. 9, 638187 (2021)
- Relevance of VEGF and CD147 in different SARS‐CoV‐2 positive digestive tracts characterized by thrombotic damage: D. Bortolotti, et al.; FASEB J. 35, e21969 (2021)
- SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation: L. Perico, et al.; Front. Immunol. 13, 827146 (2022)